Acute malignant myelosclerosis. Evidence for a panmyelotic disturbance of cellular differentiation

Targeted-therapy in advanced renal cell carcinoma.

Current medicinal chemistry·2011

Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.

In vivo (Athens, Greece)·2007

Thyroid metastases from colon cancer case report in a long term survivor.

Journal of experimental & clinical cancer research : CR·2006

Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.

Journal of experimental & clinical cancer research : CR·2006

Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study.

Journal of chemotherapy (Florence, Italy)·2005

Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone.

Journal of chemotherapy (Florence, Italy)·2005

Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia.

Haematologica·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Protecting sickle cell care during Ebola outbreaks.

Haematologica·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Haematologica·2026

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Haematologica·2026

Baseline fluconazole heteroresistance and risk of relapse within six months among patients with neurocryptococcosis in the Brazilian Amazon.

Medical mycology·2026

Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

The British journal of dermatology·2026

Mohs Micrographic Surgery After Previous Nonsurgical Treatment in Basal and Squamous Cell Carcinoma: A Scoping Review of Diagnostic Challenges.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026

Clinical isolates of Mycobacterium avium complex reveal an M. intracellulare-associated IL-17/neutrophilic pulmonary immune program in a murine disease model.

mSphere·2026

Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Recurrent Hydropneumothorax as an Initial Presentation of Malignant Pleural Mesothelioma: Diagnostic Challenges and the Evolving Role of Pleural Fluid Cytology.

Cureus·2026

Related Experiment Videos

Acute malignant myelosclerosis. Evidence for a panmyelotic disturbance of cellular differentiation

Related Concept Videos

Targeted-therapy in advanced renal cell carcinoma.

Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.

Thyroid metastases from colon cancer case report in a long term survivor.

Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.

Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study.

Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone.

Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia.

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Protecting sickle cell care during Ebola outbreaks.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Baseline fluconazole heteroresistance and risk of relapse within six months among patients with neurocryptococcosis in the Brazilian Amazon.

Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

Mohs Micrographic Surgery After Previous Nonsurgical Treatment in Basal and Squamous Cell Carcinoma: A Scoping Review of Diagnostic Challenges.

Clinical isolates of Mycobacterium avium complex reveal an M. intracellulare-associated IL-17/neutrophilic pulmonary immune program in a murine disease model.

Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

Recurrent Hydropneumothorax as an Initial Presentation of Malignant Pleural Mesothelioma: Diagnostic Challenges and the Evolving Role of Pleural Fluid Cytology.

Related Experiment Videos

Acute malignant myelosclerosis. Evidence for a panmyelotic disturbance of cellular differentiation

Related Concept Videos

Related Articles